1. Scrip
  2. >>Business

Almirall Extends Dermatology Reach With Dermira Lebrikizumab Deal

 
• By Sten Stovall

Almirall has re-affirmed its dermatology emphasis by entering a lebrikizumab option and license pact with Dermira for treating eczema in Europe.

Atopic dermatitis
Lebrikizumab is being tested in moderate-to-severe atopic dermatitis • Source: Shutterstock

Reiterating its commitment to dermatology, Almirall SA has entered a deal with US-based Dermira Inc. for the investigational anti-IL-13 monoclonal antibody lebrikizumab. The family-controlled Spanish group gets an option to exclusively license European rights to develop and commercialize lebrikizumab to treat atopic dermatitis, for which Dermira gets an upfront option fee of $30m.

If Almirall exercises its option to obtain the license - following receipt of data from an ongoing Phase IIb lebrikizumab study - Dermira will receive a $50m option exercise fee and be eligible for development, regulatory and sales

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.